CollPlant Biotechnologies (CLGN) Corporate Presentation summary

Technology platform and product innovation

• Produces recombinant human collagen (rhCollagen) in genetically engineered tobacco plants at mass scale, offering a xeno-free, non-immunogenic, and structurally identical alternative to human type I collagen.

• rhCollagen demonstrates superior biofunctionality, safety, and homogeneity compared to animal-derived collagen, enabling faster tissue repair and reduced risk of immune rejection.

• The technology is supported by a comprehensive master file detailing genetic, molecular, and physical characterizations, ensuring quality and reproducibility.

Product pipeline and market focus

• Pipeline includes dermal/soft tissue fillers (clinical phase, in collaboration with AbbVie), 3D bioprinted breast implants (preclinical), and commercial bioinks for tissue and organ bioprinting.

• Dermal fillers combine rhCollagen and hyaluronic acid, offering enhanced cell adhesion, tissue regeneration, and non-immunogenic properties.

• Photocurable fillers allow in-situ hardening, precise contouring, and long-lasting, natural-looking results, with positive feedback from key opinion leaders.

• 3D bioprinted breast implants aim to address safety and regenerative needs unmet by silicone implants, with preclinical animal studies showing promising tissue growth and integration.

• Bioinks are commercially available, animal-free, and compatible with major 3D printing technologies, supporting scalable and reproducible tissue engineering.

Market opportunity and strategic partnerships

• Addresses multi-billion-dollar global markets in medical aesthetics and regenerative medicine, including a $6.3B dermal filler market and $3.0B breast implant market.

• Strategic agreement with AbbVie allows for up to $103M in milestone payments and additional royalties, supporting clinical development and commercialization.

• In-house cGMP production facility ensures sustainable, environmentally responsible manufacturing.